|
Mitchell Glass is a 22 year veteran of the pharmaceutical industry with experiences ranging from senior positions in top ten pharmaceutical companies to investment in and management of start-ups and biotechs. After 7 years of research, teaching and patient care (University of Pennsylvania), Dr. Glass joined ICI Pharmaceuticals in 1988 where he established the pulmonary therapeutics group and led the development and submission (1988-95) of the antileukotriene ACCOLATE. From 1995-6, Dr. Glass was VP and Director at SmithKline Beecham where he was responsible for cardiovascular, respiratory, renal and metabolic drug development and commercialization, including submission of the NDA/MAA for COREG and TEVETEN and the Phase 3 development of AVANDIA.
From 1998 to 2005, Dr. Glass was Chief Medical Officer and VP of Clinical Development and Regulatory Affairs of AtheroGenics, Inc. (AGIX), where he led lead product development from IND to initiation of Phase 3 for AGI 1067 and was a member of the IPO team.
After a stint (2005-6) as Chief Scientific Officer of the University City Science Center (Philadelphia), Dr. Glass joined AQUMEN Biopharmaceuticals KK and NA as CEO of AQUMEN NA and a Main Board Director. Since 2008, Dr. Glass has been a Director of OrphageniX, Inc. (gene editing) and AVATAR Biotechnologies (biosimilars) and a consultant in R&D and fundraising to early stage therapeutics companies.
Dr. Glass graduated the U of Chicago (AB'73, MD77) and is Board certified in internal medicine, pulmonary and critical care medicine.
|
